{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T15:42:40Z","timestamp":1649173360843},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/mnm.0b013e32835ce596","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T12:32:06Z","timestamp":1356957126000},"page":"265-270","source":"Crossref","is-referenced-by-count":2,"title":["Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors"],"prefix":"10.1097","volume":"34","author":[{"given":"Giorgio","family":"Biasiotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Biasiotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Savelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Bettinsoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chinol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210212","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1023\/A:1012272314550","article-title":"Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients.","volume":"2","author":"Quaedvlieg","year":"2001","journal-title":"Ann Oncol"},{"key":"R2-10-20210212","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"5-Decade analysis of 13 715 carcinoid tumors.","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"R3-10-20210212","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10620-006-9345-4","article-title":"Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.","volume":"51","author":"Clancy","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R4-10-20210212","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.surg.2007.01.036","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival.","volume":"142","author":"Mazzaglia","year":"2007","journal-title":"Surgery"},{"key":"R5-10-20210212","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF02557521","article-title":"Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.","volume":"9","author":"Chu","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"R6-10-20210212","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"R7-10-20210212","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2214\/AJR.06.0933","article-title":"Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.","volume":"188","author":"Ho","year":"2007","journal-title":"Am J Roentgenol"},{"key":"R8-10-20210212","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<530::AID-IJC7>3.0.CO;2-Z","article-title":"Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.","volume":"70","author":"Schaer","year":"1997","journal-title":"Int J Cancer"},{"key":"R9-10-20210212","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-10-20210212","first-page":"792","article-title":"DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.","volume":"24","author":"Otte","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"R11-10-20210212","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1002\/cncr.26616","article-title":"Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of (90)Y-DOTA-D-Phe1-Tyr3 octreotide.","volume":"118","author":"Savelli","year":"2012","journal-title":"Cancer"},{"key":"R12-10-20210212","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s002590100502","article-title":"Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.","volume":"28","author":"Breeman","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R13-10-20210212","first-page":"553","article-title":"Testing of microbial contamination during the preparation of the radiocompound 90YDOTATOC for clinical trials: a process validation study by Media Fill approach.","volume":"54","author":"Sirna","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R14-10-20210212","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","article-title":"Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.","volume":"30","author":"Breeman","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-10-20210212","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of 90Y-DOTA-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"R16-10-20210212","first-page":"792","article-title":"DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.","volume":"24","author":"Otte","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"R17-10-20210212","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/snuc.2002.31563","article-title":"Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group.","volume":"32","author":"Chinol","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R18-10-20210212","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/bip.10349","article-title":"90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.","volume":"66","author":"Paganelli","year":"2002","journal-title":"Biopolymers"},{"key":"R19-10-20210212","first-page":"368","article-title":"Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of DOTA0,D-Phe1,Tyr3octreotide, a promising somatostatin analogue for radionuclide therapy.","volume":"24","author":"De Jong","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"R20-10-20210212","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-10-20210212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10967-007-7186-z","article-title":"Quality control of no-carrier-added 90YCl3 by estimating the labelling efficiency using its reaction with DOTATOC.","volume":"278","author":"Eigner Henke","year":"2008","journal-title":"J Radioanal Nucl Ch"},{"key":"R22-10-20210212","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X","article-title":"Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy.","volume":"5","author":"Heppeler","year":"1999","journal-title":"Chem Eur J"},{"key":"R24-10-20210212","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14653240802075476","article-title":"A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products.","volume":"10","author":"Gee","year":"2008","journal-title":"Cytotherapy"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0b013e32835ce596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:18:41Z","timestamp":1620962321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201303000-00010"}},"subtitle":["results of 85 syntheses"],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e32835ce596","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}